Neuronopathic gaucher disease

Gaucher Disease

Volumn , Issue , 2006, Pages 175-196

  Schiffmann, Raphael ^a   Vellodi, Ashok ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892888218     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420005509     Document Type: Chapter

References (102)

1. Charrow, J. et al., The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med, 160, 2835, 2000.
2. Ida, H. et al., Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation. Hum Genet, 105, 120, 1999.
3. Eto, Y. and Ida, H., Clinical and molecular characteristics of Japanese Gaucher disease. Neurochem Res, 24, 207, 1999.
4. Drugan, C. et al., Gaucher disease in Romanian patients: incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet, 10, 511, 2002.
5. Alfonso, P. et al., Mutation prevalence among 51 unrelated Spanish patients with Gaucher disease: identification of 11 novel mutations. Blood Cells Mol Dis, 27, 882, 2001.
6. Rusca, C.L., Sul morbo del Gaucher. Hematoogica (Pavia), 2, 441, 1921.
7. Oberling, C. and Woringer, P., La maladie de Gaucher chez le nourisson. Rev Franc de Pediatr, 3, 475, 1927.
8. Lachiewicz, P.F., Gaucher’s disease. Orthop Clin North Am, 15, 765, 1984.
9. Glew, R.H. et al., Enzymic differentiation of neurologic and nonneurologic forms of Gaucher’s disease. J Neuropathol Exp Neurol, 41, 630, 1982.
10. Brady, R.O., Barton, N.W., and Grabowski, G.A., The role of neurogenetics in Gaucher disease. Archives of Neurology, 50, 1212, 1993.
11. Patterson, M.C. et al., Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology, 43, 1993, 1993.
12. Goker-Alpan, O. et al., Phenotypic continuum in neuronopathic Gaucher disease: An intermediate phenotype between type 2 and type 3. J Pediat, 143, 273, 2003.
13. Sidransky, E., Gaucher disease: complexity in a “simple” disorder. Mol Genet Metab, 83, 6, 2004.
14. Chabas, A. et al., Neuronopathic and non-neuronopathic presentation of Gaucher disease in patients with the third most common mutation (D409H) in Spain. J Inh Metab Dis, 19, 798, 1996.
15. Bohlega, S. et al., Gaucher disease with oculomotor apraxia and cardiovascular calcification (Gaucher type IIIC). Neurology, 54, 261, 2000.
16. Sidransky, E. et al., Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res, 39, 134, 1996.
17. Bove, K.E., Daugherty, C., and Grabowski, G.A., Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol, 26, 1040, 1995.
18. Kaye, E.M. et al., Type 2 and type 3 Gaucher disease: a morphological and biochemical study. Ann Neurol, 20, 223, 1986.
19. Takahashi, T. et al., Enzyme therapy in Gaucher disease type 2: an autopsy case. Tohoku J Exp Med, 186, 143, 1998.
20. Sinclair, G., Choy, F.Y.M., and Humphries, L., A novel complex allele and two new point mutations in type 2 (acute neuronopathic) Gaucher disease. Blood Cells Mole Dis, 24, 420, 1998.
21. Frederickson, D.S. and Sloan, H.R., Glucosylceramide lipidoses - Gaucher’s disease, in The Metabolic Basis of Inherited Disease, Stanbury, J.B., Fredrickson, D.S., Eds., McGraw-Hill, New York, 1972, 730-759.
22. Vellodi, A. et al., Management of neuronopathic Gaucher disease: a European consensus. J Inher Metabol Dis, 24, 319, 2001.
23. Lui, K. et al., Collodion babies with Gaucher’s disease. Arch Dis Child, 63, 854, 1988.
24. Soma, H. et al., Identification of Gaucher cells in the chorionic villi associated with recurrent hydrops fetalis. Placenta, 21, 412, 2000.
25. Tybulewicz, V.L. et al., Animal model of Gaucher’s disease from targeted disruption of the mouse glucocerebrosidase gene. Nature, 357, 407, 1992.
26. Stone, D.L. et al., Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease? Eur J Hum Genet, 7, 505, 1999.
27. Schiffmann, R. et al., Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher’s disease. Ann Neurol, 42, 613, 1997.
28. Harris, C.M., Taylor, D.S., and Vellodi, A., Ocular motor abnormalities in Gaucher disease. Neuropediatrics, 30, 289, 1999.
29. Harris, C.M. et al., Morbus Gaucher. Auditory brainstern response and eye movement in diagnosis of Morbus Gaucher type 3. Monatsschrift Kinderheilkunde, 151, 854, 2003.
30. Altarescu, G. et al., The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher’s disease. J Pediatr, 138, 539, 2001.
31. Germain, D.P., Gaucher disease: clinical, genetic and therapeutic aspects. Pathologie Biologie, 52, 343, 2004.
32. Erikson, A., Bembi, B., and Schiffmann, R., Neuronopathic forms of Gaucher’s disease. Baillieres Clin Haematol, 10, 711, 1997.
33. Erikson, A., Gaucher disease - Norrbottnian type (III). Neuropaediatric and neurobiological aspects of clinical patterns and treatment. Acta Paediatr Scand Suppl, 326, 1, 1986.
34. Frei, K.P. and Schiffmann, R., Myoclonus in Gaucher disease. Adv Neurol, 89, 41, 2002.
35. Abrahamov, A. et al., Gaucher’s disease variant characterised by progressive calcification of heart valves and unique genotype. Lancet, 346, 1000, 1995.
36. Tripp, J.H. et al., Juvenile Gaucher ‘s disease with horizontal gaze palsy in three siblings. J Neurol Neurosurg Psychiatry, 40, 470, 1977.
37. Steinlin, M., Thunhohenstein, L., and Boltshauser, E. Congenital Oculomotor Apraxia - Presentation, Developmental Problems and Differential-Diagnosis. Klinische Monatsblatter Fur Augenheilkunde, 200, 623, 1992.
38. Bamiou, D.E. et al., Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics, 32, 136, 2001.
39. Campbell, P.E., Harris, C.M., and Vellodi, A., Deterioration of the auditory brainstem response in children with type 3 Gaucher disease. Neurology, 63, 385, 2004.
40. Musiek, F.E. and Lee, W.W., Auditory middle and late potentials, in Contemporary Perspectives in Hearing Assessment, Musiek, F.M., Rintelmann, W.F., Eds., Allyn and Bacon, Nedham Heights, 1999.
41. Zupanc, M.L. and Legros, B., Progressive myoclonic epilepsy. Cerebellum, 3, 156, 2004.
42. Rapin, I. Myoclonus in neuronal storage and Lafora diseases. Advances in neurology, 43, 65, 1986.
43. Manganotti, P. et al., Hyperexcitable cortical responses in progressive myoclonic epilepsy: a TMS study. Neurology, 57, 1793, 2001.
44. Garvey, M.A. et al., Somatosensory evoked potentials as a marker of disease burden in type 3 Gaucher disease. Neurology, 56, 391, 2001.
45. Verghese, J., et al., Myoclonus from selective dentate nucleus degeneration in type 3 Gaucher disease. Arch Neurol, 57, 389, 2000.
46. Wenger, D.A. et al., Biochemical studies in a patient with subacute neuropathic Gaucher disease without visceral glucosylceramide storage. Pediatr Res, 17, 344, 1983.
47. Sack, G.H., Jr., Clinical diversity in Gaucher’s disease. Johns Hopkins Med J, 146, 166, 1980.
48. Neudorfer, O. et al., Occurrence of Parkinson’s syndrome in type I Gaucher disease. Qjm, 89, 691, 1996.
49. Neil, J.F., Glew, R.H., and Peters, S.P., Familial psychosis and diverse neurologic abnormalities in adult-onset Gaucher’s disease. Arch Neurol, 36, 95, 1979.
50. Davison, C., Disturbances of lipid metabolism and the central nervous system. J Mt Sinai Hosp, 9, 389, 1942.
51. Bembi, B. et al., Gaucher’s disease with Parkinson’s disease: clinical and pathological aspects. Neurology, 61, 99, 2003.
52. Tayebi, N. et al., Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab, 73, 313, 2001.
53. Wong, K. et al., Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab, 82, 192, 2004.
54. Dickson, D.W. et al., Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology, 41, 1402, 1991.
55. Lwin, A. et al., Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab, 81, 70, 2004.
56. Aharon-Peretz, J., Rosenbaum, H., and Gershoni-Baruch, R., Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med, 351, 1972, 2004.
57. Clark, L.N. et al., Pilot association studyof the beta-glucocerebrosidase N370S allele and Parkinson’s disease in subjects of Jewish ethnicity. Mov Disord, 20, 100, 2005.
58. Sato, C. et al., Analysis of the glucocerebrosidase gene in Parkinson’s disease. Mov Disord, 20, 367, 2005.
59. Toft, M. et al., Glucocerebrosidase gene mutations are not associated with Parkinson’s disease in the Norwegian population. Mov Disord, 20, Suppl., 10, S37, 2005.
60. Dreborg, S., Erikson, A., and Hagberg, B., Gaucher disease - Norrbottnian type. I. General clinical description. Eur J Pediatr, 133, 107, 1980.
61. Dahl, N., Hillborg, P.O., and Olofsson, A., Gaucher disease (Norrbottnian type 3): probable founders identified by genealogical and molecular studies. Hum Genet, 92, 513, 1993.
62. Feroze, M., Arvindan, K.P., and Jose, L., Gaucher’s disease among Mappila Muslims of Malabar. Indian J Pathol Microbiol, 37, 307, 1994.
63. Park, J.K. et al., Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup. Pediatr Res, 53, 387, 2003.
64. Zhao, H. et al., Gaucher disease: In vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypes. Am J Med Genet, 116, 52, 2003.
65. Ron, I. and Horowitz, M., ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet, 14, 2387, 2005.
66. Cox, T.M. and Schofield, J.P., Gaucher’s disease: clinical features and natural history. Baillieres Clin Haematol, 10, 657, 1997.
67. Brady, R.O., Kanfer, J.N., and Shapiro, D., Metabolism of glucosylcerebroside II. Enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun, 18, 221, 1965.
68. Pelled, D. et al., Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis, 18, 83, 2005.
69. Xu, Y.H. et al., Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol, 163, 2093, 2003.
70. Lloyd-Evans et al., Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Bio Chem, 278, 23594, 2003.
71. Korkotian, E. et al., Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem, 274, 21673, 1999.
72. Schueler, U.H. et al., Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis, 14, 595, 2003.
73. Orvisky, E. et al., Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype. Mol Genet Metab, 76, 262, 2002.
74. Tayebi, N. et al., Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? Mol Genet Metab, 79, 104, 2003.
75. Stone, D.L. et al., Type 2 Gaucher disease: the collodion baby phenotype revisited. Arch Dis Child Fetal Neonatal Ed, 82, F163, 2000.
76. Yoshikawa, H. et al., Uncoupling of blood flow and oxygen metabolism in the cerebellum in type 3 Gaucher disease. Brain Dev, 13, 190, 1991.
77. Chang, Y.C. et al., MRI in acute neuropathic Gaucher’s disease. Neuroradiology, 42, 48, 2000.
78. Migita, M. et al., Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy - unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease. Eur J Pediatr, 162, 524, 2003.
79. Erikson, A., Remaining problems in the management of patients with Gaucher disease. J Inher Metab Dis, 24 Suppl. 2, 122, 2001.
80. Lee, S.Y. et al., Gaucher disease with pulmonary involvement in a 6-year-old girl: report of resolution of radiographic abnormalities on increasing dose of imiglucerase. J Pediatr, 139, 862, 2001.
81. Lim, A.K., Vellodi, A., and McHugh, K., Mesenteric mass in a young girl - an unusual site for Gaucher’s disease. Pediatr Radiol, 32, 674, 2002.
82. Eto, Y. and Ohashi, T. Novel treatment for neuronopathic lysosomal storage diseasescell therapy/gene therapy. Curr Mol Med, 2, 83, 2002.
83. Ono, H. et al., Neurological features in Gaucher’s disease during enzyme replacement therapy. Acta Paediatr, 90, 229, 2001.
84. Michelakakis, H. et al., Early-onset severe neurological involvement and D409H homozygosity in Gaucher disease: outcome of enzyme replacement therapy. Blood Cells Molecules and Diseases, 28, 1, 2002.
85. Pelled, D., Shogomori, H., and Futerman, A.H., The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inher Metabol Dis, 23, 175, 2000.
86. Tsai, P. et al., Allogenic bone marrow transplantation in severe Gaucher disease. Pediatr Res, 31, 503, 1992.
87. Erikson, A. et al., Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand, 79, 680, 1990.
88. Ringden, O. et al., Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. Transplantation, 46, 66, 1988.
89. Kapelushnik, J. et al., Bone marrow transplantation from a cadaveric donor. Bone Marrow Trans, 21, 857, 1998.
90. Hobbs, J.R. et al., Beneficial effect of pre-transplant splenectomy on displacement bone marrow transplantation for Gaucher’s syndrome. Lancet, 1, 1111, 1987.
91. Zirzow, G.C. et al., Delivery, distribution, and neuronal uptake of exogenous mannose- terminal glucocerebrosidase in the intact rat brain. Neurochem Res, 24, 301, 1999.
92. Lonser, R.R. et al., Convective perfusion of glucocerebrosidase for neuronopathic Gaucher disease. Ann Neurol 2005, 57, 542, 2005.
93. Lee, K.O. et al., Improved intracellular delivery of glucocerebrosidase mediated by the HIV-1 TAT protein transduction domain. Biochem Biophys Res Commun, 337, 701, 2005.
94. Cox, T.M. et al., The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inher Metab Dis, 26, 513, 2003.
95. Cox, T. et al., Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet, 355, 1481, 2000.
96. Heitner, R. et al., Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis, 28, 127, 2002.
97. Ishii, S. et al., Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease. Biochim Biophys Acta, 1690, 250, 2004.
98. Pal, S. et al., Epileptogenesis induces long-term alterations in intracellular calcium release and sequestration mechanisms in the hippocampal neuronal culture model of epilepsy. Cell Calcium, 30, 285, 2001.
99. Mattson, M.P. et al., Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci, 23, 222, 2000.
100. Matzner, U. and Gieselmann, V. Gene therapy of metachromatic leukodystrophy. Expert Opin Biol Ther, 5, 55, 2005.
101. Hartung, S.D. et al., Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther, 9, 866, 2004.
102. Cheng, S.H. and Smith, A.E. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther, 10, 1275, 2003.